Catriona Yale, the Chief Development Officer of $AKRO, sold 14,467 shares of the company on 01-27-2025 for an estimated $809,428. We received data on the trade from a ...
In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against the other stocks. Wall Street ended the first trading day of the week on a mixed note ...
Timothy Rolph, the Chief Scientific Officer of $AKRO ($AKRO), sold 2,450 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing ...
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Akero Therapeutics (AKRO – Research Report) on January 27 and set a price target of $73.00. The company’s shares closed yesterday at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback